Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 36 of 581 for:    reduced glutathione

Analysis of the Glutathione Cycle in Children With Rett Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02360436
Recruitment Status : Withdrawn (Priorities other studies)
First Posted : February 10, 2015
Last Update Posted : January 20, 2016
Sponsor:
Information provided by (Responsible Party):
Edison Pharmaceuticals Inc

Brief Summary:
Analyis of the Glutathione Cycle in Children with Rett Syndrome

Condition or disease
Rett Syndrome

Detailed Description:
To analyze the levels of glutathione and relevant glutathione metabolites in children with Rett syndrome in an effort to better understand disease pathology and biochemistry.

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: EPITRA-14-001: Analysis of the Glutathione Cycle in Children With Rett Syndrome
Study Start Date : March 2015
Estimated Primary Completion Date : July 2015
Estimated Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rett Syndrome
Drug Information available for: Glutathione




Primary Outcome Measures :
  1. Analysis of changes in levels of glutathione and relevant glutathione metabolites in children with Rett syndrome from baseline to the end of month 6 [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children aged 2-10 with genetically confirmed diagnosis of Rett syndrome with MeCP2 mutation
Criteria

Inclusion Criteria:

  • Age between 2 and 10, inclusive
  • Genetically-confirmed diagnosis of Rett syndrome with MeCP2 mutation
  • No change in dietary supplements in three months prior to the initial blood draw
  • No participation in interventional pharmaceutical clinical trials in prior 12 months

Exclusion Criteria:

  • None other than meeting Inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02360436


Locations
Layout table for location information
United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
Edison Pharmaceuticals Inc
Investigators
Layout table for investigator information
Principal Investigator: Alan Percy, MD University of Alabama at Birmingham

Additional Information:
Layout table for additonal information
Responsible Party: Edison Pharmaceuticals Inc
ClinicalTrials.gov Identifier: NCT02360436     History of Changes
Other Study ID Numbers: EPITRA-14-001
First Posted: February 10, 2015    Key Record Dates
Last Update Posted: January 20, 2016
Last Verified: February 2015

Keywords provided by Edison Pharmaceuticals Inc:
Rett
MeCP2
Glutathione
Cysteine
ROS

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Rett Syndrome
Disease
Pathologic Processes
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System